Clarametyx Biosciences’ Post

Kineticos is excited to announce our investment into Clarametyx Biosciences through our Kineticos AMR Accelerator Fund I, L.P. Clarametyx is driving innovation in antimicrobial resistance through their clinical trial in cystic fibrosis-related infections and development of their vaccine against recurrent bacterial infections. We look forward to working with David V. Richards and the entire Clarametyx team as they take on the challenge of AMR. #AMR #antimicrobialresistance #cysticfibrosis

Hong Kong based ORI Capital recently final closed their second fund, ORI Fund II. 💸 $260 Million total commitments for Second Life Sciences Fund 💡 Growth-oriented venture investments into early-stage #biotech companies in the areas of #diagnostics, #drugdelivery, and #therapeutics focused on the disease areas with the highest mortality rates: cancer, cardiovascular and neurodegenerative diseases. 🌍 Globally 📈 Notable exits include: CG Oncology’s, Orchard Therapeutics - U.S. and TriSalus Life Sciences Nasdaq listings; and Semma Therapeutics which was acquired by Vertex in 2019 for $950 million in cash. Current portfolio companies include Pillar Biosciences Incorporated, AffyImmune Therapeutics and Enable Injections, Inc.. 💭 “We are in a golden-era of innovation across the intersection of #AI and biology, where technological breakthroughs are creating new approaches to diagnosing and treating disease” - Simone Song, Founding Partner, ORI Capital 🗞️By Business Wire https://lnkd.in/dZRgED2U 👏 For the #AudaciousInvestors unleashing innovation and empowering tomorrow🚀 Simone Song I Dicky To I Gang Song I Elaine Yang I Arnold Ching, I Danny Wong I Anthony S. I Nico Zheng I Sarah Oi Kwan Mak I Otto Cheung I Edward Tung I Team Ori … #venturecapital #vc #funds #startups #entrepreneurs #funding #tech #ai #entrepreneurship #technology #innovation #bigdata #hongkong #asia

GEMMABio's seed round investment has completed! With support from Double Point Ventures, Bioluminescence Ventures, Earlybird Venture Capital, and Bioculture Group (Savanne Life Sciences), we will advance our mission to bring transformative therapies to the rare disease community.

One of the biotech industry's star investors, the 38-year-old VC firm ARCH Venture Partners, uncorked its 13th fund on Thursday. The Chicago-based firm has another $3 billion to deploy into its large bets on neuroscience, AI, obesity, autoimmune diseases and other areas ripe for more precise treatments. “We’re trying to slow down, but not slowing down because there’s so much cool stuff right now,” managing director Bob Nelsen said Wednesday in an interview with Endpoints News. “Every time we think we’re going to slow down, AI happens or some other thing happens, so it’s an amazing environment to start companies, small ones or big ones, and we do both.” The firm has dished out larger checks and created more startups than most other biotech VC investors over the years. Its current roster includes Xaira Therapeutics, Mirador Therapeutics, Seaport Therapeutics and Metsera among dozens of others. “I’m very hopeful over the next 10 years, and certainly the life of Fund XIII, that we’ll continue to evolve the precision medicine models so that we can better serve patients with lupus, with rheumatoid arthritis, with metabolic disease, cardiovascular disease,” managing director Kristina Burow said in an interview. “Those aren’t just giant, lump diseases. We’re going to start to be able to parse different patients into different medicines.” #biotech #venturecapital #arch #biotechvc #vcfirm #lifesciences

Exciting news from our portfolio company Citryll that closed an oversubscribed Series B financing of € 85 million to progress their lead compound CIT-013 into two phase 2a trials in #RA and #HS patients. We welcome the renowned new investors Forbion, Johnson & Johnson JJDC, Novartis Venture Fund, and Pureos Bioventures to the syndicate. Curie Capital BV is proud to support the development of CIT-013 targeting #NETs in auto-immune diseases and the strong Citryll team since 2019 together with Brabantse Ontwikkelings Maatschappij (BOM), ModiQuest B.V. and then joined by BGV (BioGeneration Ventures) and Seventure Partners. https://lnkd.in/eHgeRcnA

Adcendo, a Copenhagen, Denmark-based biotech company focused on developing ADCs for the treatment of cancers with a high unmet medical need, raised $135M in Series B funding. The round was led by TCGX, with participation from new investors TPG Life Sciences Innovations, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, as well as all existing investors, including RA Capital Management, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, a platform controlled by KKR, HealthCap, Gilde Healthcare and Ysios Capital. The company intends to use the funds to advance, broaden, and accelerate the development of its ADC pipeline, including the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05 and A0401 programs. https://lnkd.in/gi8U6_2E

🚀💼🔬 Radiopharma Fundings (2024): Insights and Trends 🔬 📊 Investment Overview: In 2024, the radiopharmaceutical industry witnessed significant funding events. Here are some key takeaways: ▶ In just 4 months and 22 days: 8 companies raised ~💲270M 💰 & deals worth ~💲5.47B 💰(Part 1 post: https://lnkd.in/gA3dY-i4) ▶Series B Funding Dominates: Series B funding rounds were the most common, indicating growing confidence in Radiopharma startups. ▶Diverse Investors: A mix of venture capital firms, private equity, and family offices participated. Notable investors include Prosperity7 Ventures, Sky9 Capital, and Schusterman Family Investments (SFI) and more. ▶Focus on Oncology: Most investments targeted cancer treatments, especially pancreatic and prostate cancers. The industry is rallying to address unmet medical needs. ▶Public vs. Private: While some companies went public (like Plus Therapeutics, Inc.), others remained private. The choice depends on growth strategies and market readiness. 🔗#RadiopharmaInvestment #HealthcareInnovation #PharmaTrends 📩 Connect with Me: Feel free to reach out if you’d like more insights or have questions! Let’s drive radiopharma forward together. 🌟 Remember, the radiopharmaceutical field is evolving rapidly. Adaptability and collaboration are key. 🤝 #Radiopharma #InvestmentTrends #LinkedInPost Disclaimer: The information provided is based on publicly available data and does not constitute financial advice.

GEMMABio, a new biotherapeutics company founded by James M. Wilson, MD, PhD, has completed its seed round with investments from Double Point Ventures, Bioluminescence Ventures, Earlybird Venture Capital, and Bioculture Group (Savanne Life Sciences)! Read more here: https://lnkd.in/e6hh7q7t

...The Series B financing, which brought the total capital raised to approximately $200m, was led by RA Capital Management, with participation from new investors Qatar Investment Authority (QIA), Surveyor Capital (a Citadel company), #SheatreeCapital, Black Opal Ventures, Keller Williams Realty, Alexandria Ventures, LLC , and other undisclosed investors, and existing investors ARTIS Ventures, Playground Global, Bristol Myers Squibb, Abstract Ventures, Civilization Ventures, Mubadala Capital, Breton Capital Ventures, Washington Research Foundation (WRF) Capital, and Sahsen Ventures, LLC Ventures. Jake Simson, PhD, Partner at RA Capital Management has been appointed to the company’s Board of Directors. Led by Marc Lajoie, PhD, Co-Founder & Chief Executive Officer, Outpace Bio is advancing an internal pipeline of engineered T cell therapies for the treatment of solid tumors.... #seriesB #solidtumors #200m #SeriesB144m #tcelltherapies #capital #celltherapy #cellandgenetherapy #CarT #regenerativemedicine #advancedtherapies #investment #AIpoweredproteindesign #AI #cellprogramming #biotech #biotechnology #pipeline #oncology #cancer #lifescience #lifesciences #therapeutics

Aspect Biosystems Raises $115M for Bioprinted Tissue Therapeutics The round was led by Dimension, a multistage investment firm “dedicated to the interface of technology and the life sciences,” with participation from Novo Nordisk, Radical Ventures, an undisclosed leading global investment firm, InBC, Pallasite Ventures Inc., Pangaea Ventures, Rhino Ventures, and T1D Fund: A Breakthrough T1D Venture.